TY - JOUR
T1 - Coronary fluorine-18-sodium fluoride uptake is increased in healthy adults with an unfavorable cardiovascular risk profile
T2 - results from the CAMONA study
AU - Blomberg, Björn A.
AU - Thomassen, Anders
AU - de Jong, Pim A
AU - Lam, Marnix G E
AU - Diederichsen, Axel C P
AU - Olsen, Michael H
AU - Mickley, Hans
AU - Mali, Willem P T M
AU - Alavi, Abass
AU - Høilund-Carlsen, Poul F.
N1 - Publisher Copyright:
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Objective Coronary artery fluorine-18-sodium fluoride (
18F-NaF) uptake reflects coronary artery calcification metabolism and is considered to be an early prognostic marker of coronary heart disease. This study evaluated the relationship between coronary artery
18F-NaF uptake and cardiovascular risk in healthy adults at low cardiovascular risk. Participants and methods Study participants underwent blood pressure measurements, blood analyses, and coronary artery
18F-NaF PET/CT imaging. In addition, the 10-year risk for the development of cardiovascular disease, on the basis of the Framingham Risk Score, was estimated. Multivariable linear regression evaluated the dependence of coronary artery
18F-NaF uptake on cardiovascular risk factors. Results We recruited 89 (47 men, 42 women) healthy adults aged 21-75 years. Female sex (0.34 kBq/ml; P=0.009), age (0.16 kBq/ml per SD; P=0.002), and BMI (0.42 kBq/ml per SD; P<0.001) were independent determinants of increased coronary artery
18F-NaF uptake (adjusted R 2 =0.21; P<0.001). Coronary artery
18F-NaF uptake increased linearly according to the number of cardiovascular risk factors present (P<0.001 for a linear trend). The estimated 10-year risk for the development of cardiovascular disease was on average 2.4 times higher in adults with coronary artery
18F-NaF uptake in the highest quartile compared with those in the lowest quartile of the distribution (8.0 vs. 3.3%, P<0.001). Conclusion Our findings indicate that coronary artery
18F-NaF PET/CT imaging is feasible in healthy adults at low cardiovascular risk and that an unfavorable cardiovascular risk profile is associated with a marked increase in coronary artery
18F-NaF uptake.
AB - Objective Coronary artery fluorine-18-sodium fluoride (
18F-NaF) uptake reflects coronary artery calcification metabolism and is considered to be an early prognostic marker of coronary heart disease. This study evaluated the relationship between coronary artery
18F-NaF uptake and cardiovascular risk in healthy adults at low cardiovascular risk. Participants and methods Study participants underwent blood pressure measurements, blood analyses, and coronary artery
18F-NaF PET/CT imaging. In addition, the 10-year risk for the development of cardiovascular disease, on the basis of the Framingham Risk Score, was estimated. Multivariable linear regression evaluated the dependence of coronary artery
18F-NaF uptake on cardiovascular risk factors. Results We recruited 89 (47 men, 42 women) healthy adults aged 21-75 years. Female sex (0.34 kBq/ml; P=0.009), age (0.16 kBq/ml per SD; P=0.002), and BMI (0.42 kBq/ml per SD; P<0.001) were independent determinants of increased coronary artery
18F-NaF uptake (adjusted R 2 =0.21; P<0.001). Coronary artery
18F-NaF uptake increased linearly according to the number of cardiovascular risk factors present (P<0.001 for a linear trend). The estimated 10-year risk for the development of cardiovascular disease was on average 2.4 times higher in adults with coronary artery
18F-NaF uptake in the highest quartile compared with those in the lowest quartile of the distribution (8.0 vs. 3.3%, P<0.001). Conclusion Our findings indicate that coronary artery
18F-NaF PET/CT imaging is feasible in healthy adults at low cardiovascular risk and that an unfavorable cardiovascular risk profile is associated with a marked increase in coronary artery
18F-NaF uptake.
KW - PET/CT
KW - fluorine-18-sodium fluoride
KW - atherosclerosis
KW - vascular calcification
U2 - 10.1097/MNM.0000000000000734
DO - 10.1097/MNM.0000000000000734
M3 - Article
C2 - 28877084
SN - 0143-3636
VL - 38
SP - 1007
EP - 1014
JO - Nuclear Medicine Communications
JF - Nuclear Medicine Communications
IS - 11
ER -